PPT-Hyperglycemia: DKA and HHS

Anne Marie Mattingly Assistant Professor of Medicine Division of Pulmonary and Critical Care September 22 2014 Goals of Treatment Accurately diagnose DKA andor HHS Provide optimal volume resuscitation. S-KHALILZADEH. BIOCHEMISTRY AND MOLECULAR CELL BIOLOGY. All forms of diabetes, both inherited and acquired, are characterized by hyperglycemia, a relative or absolute lack of insulin, and the development of diabetes-specific . RELATIONSHIPbetweenadmissionplasmaglucoseconcentrationandin-hospitalmortalityinpatientswithacutemyocardialinfarctionandacutestrokehasbeenestablished(1 الرحيم. دکتر . محمدافخمی. فوق تخصص غدد و متابولیسم . Chronic Complications of DM:. Chronic complications can be divided into vascular and nonvascular complications.. R. esistance and Diabetes. Alfred Martello, MD. Medical Director. The Ohio Anesthesia Group. Disclosures. No Commercial endorsements. I’m not really smart enough to give this lecture.. It’s really complicated stuff.. 1. Overview. 2. Inpatient Hyperglycemia and Poor Outcomes in Numerous Settings. Study. Patient Population. Significant Hyperglycemia-Related Outcomes. Pasquel et al, 2010. Total parenteral nutrition. HYPERglycemia. -HIGH. blood sugar. Participants will be able to understand:. Symptoms of . high blood sugar. Treatment of . high blood sugar. Short and long term risks of . high blood sugar. Above target range. Network Effort (SHINE) Trial . NIH-NINDS . U01 . NS069498. An Overview of SHINE. Contents. Background. Trial Overview. Treatment Groups. Outcomes. I-SPOT Ancillary Study. SHINE Background. Most animal stroke studies show that hyperglycemia at stroke onset leads to worse outcomes than . A Review of the Basic Science. 1. Prevalence of Hyperglycemia in Critically Ill Patients. 2. CIAH, critical illness associated hyperglycemia.. Plummer MP, et al. . Intensive Care Med. . 2014;40:973-980.. 1. Overview. 2. Inpatient Hyperglycemia and Poor Outcomes in Numerous Settings. Study. Patient Population. Significant Hyperglycemia-Related Outcomes. Pasquel et al, 2010. Total parenteral nutrition. NATA Position Statement:. Management of the Athlete with Type 1 Diabetes Mellitus. Journal of Athletic Training. 2007;42(4) 536-545. Diabetes Mellitus. Type I . Chronic endocrine disorder characterized by hyperglycemia. Page 1 of 15 20 % Dextrose Injection, USP 50% Dextrose Injection, USP 70% Dextrose Injection, USP In Single Dose Partial Filled Containers IV Fluid and Nutrient Replenisher Baxter Corporation Missis DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration NDA 21-436 / S-001 Attention: Kusuma Mallikaarjun, Ph.D. Dear Dr. Mallikaarjun: Please refer to your suppleme Ups and Downs. of Blood Sugars. Attendee 1 – City TX. Glucose. Danger . values - . <. 40 . g/dl; >. 1000 . g/dl. Hyperglycemia. Brain . dehydration due to . hyperosmosis. CNS . signs (cerebral, brain stem) and seizures. Soheila. . Sadeghi. What is the diagnosis ?. What are the differences between MODY and type 1 , 2 DM ?. MODYs subtypes?. Indications for genetic testing ?. What are the Benefits of Diagnosing MODY?.